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Background: Single nucleotide polymorphisms (SNPs) have been associated with many aspects of human
development and disease, and many non-coding SNPs associated with disease risk are presumed to affect gene
regulation. We have previously shown that SNPs within transcription factor binding sites can affect transcription
factor binding in an allele-specific and heritable manner. However, such analysis has relied on prior whole-genome
genotypes provided by large external projects such as HapMap and the 1000 Genomes Project. This requirement
limits the study of allele-specific effects of SNPs in primary patient samples from diseases of interest, where
complete genotypes are not readily available.
Results: In this study, we show that we are able to identify SNPs de novo and accurately from ChIP-seq data
generated in the ENCODE Project. Our de novo identified SNPs from ChIP-seq data are highly concordant with
published genotypes. Independent experimental verification of more than 100 sites estimates our false discovery
rate at less than 5%. Analysis of transcription factor binding at de novo identified SNPs revealed widespread
heritable allele-specific binding, confirming previous observations. SNPs identified from ChIP-seq datasets were
significantly enriched for disease-associated variants, and we identified dozens of allele-specific binding events in
non-coding regions that could distinguish between disease and normal haplotypes.
Conclusions: Our approach combines SNP discovery, genotyping and allele-specific analysis, but is selectively
focused on functional regulatory elements occupied by transcription factors or epigenetic marks, and will therefore
be valuable for identifying the functional regulatory consequences of non-coding SNPs in primary disease samples.
Keywords: SNPs, Transcription factors, ChIP-seq, Genotyping, Allele-specificBackground
Single nucleotide polymorphisms (SNPs) have been asso-
ciated with normal variation in biological traits as well as
many human diseases [1,2]. With recent advances in
genotyping and sequencing technologies, the number
of known SNPs has increased dramatically. Several
international collaborative projects such as the HapMap
project [3] and the 1000 Genomes Project [4] have geno-
typed millions of SNPs in hundreds of human indivi-
duals. In the dbSNP 129 build (http://www.ncbi.nlm.nih.
gov/projects/SNP/), approximately 52 million SNPs are
cataloged in humans. However, despite the availability of
these massive datasets, our understanding of the func-
tional importance of most genomic variants is still very* Correspondence: vishy.iyer@gmail.com
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reproduction in any medium, provided the orlimited. Genome-wide association (GWA) studies have
been the main method to associate genomic variants
with a variety of phenotypes including diseases. SNP
genotyping is performed in large numbers of disease
individuals and controls to find statistically significant
associations between SNPs and diseases [5]. So far, GWA
studies have identified approximately 7000 SNPs or
regions as disease associated [1], although in most cases
neither the causal SNPs nor the molecular mechanisms
are known (http://www.genome.gov/gwastudies/).
Although SNPs located within coding regions that affect
protein sequences are the most obvious candidates for
functional SNPs, among the 7000 disease associated SNPs,
only about 7% affect coding regions. For the majority of
SNPs occurring in non-coding regions and shown to be
associated with disease risk, there are two possibilities for
explaining this association. First the identified or imputed
SNPs could directly contribute to disease risk. Alternatively,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Statistics of SNP discovery









GM12878 CTCF 30,400,254 0.40% 112,999 2989(2.6%) 2.04
GM12891 CTCF 28,282,066 0.45% 137,056 3443(2.5%) 2.18
GM12892 CTCF 41,857,998 0.75% 206,349 5439(2.6%) 2.13
GM19238 CTCF 31,125,372 0.53% 154,211 7474(4.8%) 2.11
GM19239 CTCF 24,857,361 0.41% 153,092 7034(4.6%) 2.13
GM19240 CTCF 32,009,059 0.45% 144,088 7832(5.4%) 2.11
GM12878 RNAPII 85,763,827 0.55% 152,071 5720(3.8%) 2.03
GM12878 H3K4me3 74,464,458 1.95% 200,675 8231(4.1%) 1.99
FB8470 CTCF 39,394,358 0.47% 173,336 4344(2.5%) 2.11
H1 ESC CTCF 14,462,504 0.28% 94,398 2308(2.4%) 2.18
Progeria CTCF 46,925,953 0.47% 220,871 5328(2.4%) 2.06
HUVEC CTCF 21,734,605 0.32% 55,492 1117(2.0%) 2.08
GM lines are lymphoblastoid cells resequenced by the 1000 Genomes Project.
FB8470 is a normal fibroblast line and Progeria refers to a fibroblast line
obtained from patients with the disease. H1 ESCs are human embryonic stem
cells and HUVECs are human vascular endothelial cells. Ht5 regions are regions
covered by at least 5 reads in ChIP-seq data. The fraction of the genome
represented in Ht5 regions is shown. Novel SNPs are with reference to
dbSNP129. Ti/Tv is the transition to transversion ratio.
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age disequilibrium (LD) with rarer and unknown causative
SNPs that are not directly assayed or imputed [6-8]. In
either case, it raises the question of how common or rare
variants in non-coding regions could contribute to disease
risk. One explanation for the functional effects of non-
coding SNPs in introns and intergenic regions is that they
affect transcription regulation, splicing or other aspects of
RNA processing or stability [9,10]. For example, a SNP
upstream of MUC5B has been shown to regulate its
expression and is associated with familial interstitial pneu-
monia and idiopathic pulmonary fibrosis [11]. Disease-
associated SNPs have also been reported to directly affect
transcription factor binding. Two non-coding regulatory
SNPs in FGFR2 affect binding of the transcription factors
Oct-1/Runx2 and C/EBPβ, leading to an increased expres-
sion of FGFR2 in the rarer homozygous genotypes which
have increased breast cancer risk [12]. A SNP upstream of
MYC has been shown to affect the binding of transcription
factor YY1 which may serve to regulate MYC expression in
prostate cancers [13]. Two SNPs in the intronic promoter
of MDM2, an oncogene that downregulates the tumor
suppressor TP53, have independent and opposite effects on
the binding of the transcription factor SP1. However, the
combination of both SNPs into a commonly observed
haplotype reduces SP1 binding in the MDM2 promoter
and reduces breast and ovarian cancer risk, likely by redu-
cing MDM2 expression [14,15]. While these studies shed
light on the functional basis of regulatory SNPs, they
account for a very small fraction of known disease
associated non-coding SNPs.
We have previously shown that the transcription
factor CTCF exhibits allele-specific binding bias at hun-
dreds of heterozygous SNP sites in the human genome
[16]. This study and others [17] showed that not only is
there widespread allele-specific binding of transcription
factors, but suggested a genetic basis for this specificity,
with nucleotide polymorphisms directly affecting the
binding of transcription factors. In principle therefore,
it should be possible to examine transcription factor
binding and other features of gene expression such as
chromatin modifications and RNA expression levels in
disease cells to identify whether polymorphisms asso-
ciated with disease risk indeed affect transcription fac-
tor binding, chromatin, and/or RNA in an allele-specific
manner. However, most previous analyses of allele-
specific transcription factor binding and chromatin
depended upon the availability of individual genotypes
from the 1000 Genomes Project, and therefore cannot
be easily performed in primary patient samples, where
whole-genome genotyping data based on deep sequen-
cing is generally not available. We have now developed
an approach for simultaneous SNP discovery and
transcription factor allele-specific binding analysis fromChIP-seq data we have generated in the ENCODE
Project, without reference to preexisting genotyping
information. This approach has enabled us to examine
allele specific transcription factor binding in any cell
where ChIP-seq data is available and paves the way for
extending such analysis of other sequencing-based
readouts of gene regulatory mechanisms to primary cell
samples from individuals without pre-existing genotype
data.
Results
SNP discovery from ChIP-seq data
We carried out SNP discovery from ChIP-seq data that we
generated for the transcription factor CTCF in 10 human
cell lines, including six lymphoblastoid cell lines that had
been previously sequenced and genotyped by the 1000
Genomes Project, embryonic stem cells (H1 ESCs),
vascular endothelial cells (HUVEC), and normal and
disease fibroblasts (Table 1) [16,18]. In addition we carried
out SNP discovery from RNA pol II (RNAPII) and
H3K4me3 ChIP-seq data from GM12878 cells, an EN-
CODE Tier 1 cell line. Besides the above call sets which
we analyzed in detail, we also called SNPs in H3K4me3
and/or H3K27me3 ChIP-seq data generated by ENCODE
from 17 other cell lines as well as from RNA-seq data in
GM12891 to demonstrate that the pipeline is broadly
applicable (Methods). In order to identify SNPs, we
adapted the variant discovery software suite developed by
the 1000 Genomes Project, the Genome Analysis ToolKit
(GATK) [19,20]. Raw Illumina sequences were aligned to
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with BWA [21] and the alignment was first processed to
minimize the effect of duplicated reads, sequencing and
alignment errors on genotype calls. The cleaned up
alignments were then used to calculate genotype
likelihoods and initial SNP calls were made (Methods,
Additional file 1: Figure S1). Because of our interest in
examining how polymorphisms affect the binding of a
sequence-specific transcription factor, we focused
exclusively on single nucleotide substitutions and did not
consider small insertions/deletions (indels) or larger
structural variants in our analysis. While small indels were
readily observed in the ChIP-seq alignments (see below),
larger structural variants would be missed given the nature
of the ChIP-seq data. We filtered the initial SNP call set
using two methods, model based filtering and hard filter-
ing. We carried out model-based filtering as implemented
in GATK. Briefly, a Gaussian mixture model was built with
those initially called SNPs that overlapped with known
high-quality SNPs identified by the HapMap and the 1000
Genomes Projects, using their specified annotations. Then
all called SNPs were fitted into the model and thresholds
were set so that 99% of the known high-quality SNPs were
retained [19,20]. Hard filtering was a heuristic approach in
which we excluded SNPs from the initial called set that
met the following criteria: more than 2 SNPs within 10
base pairs, more than 10% of the sequence reads overlap-
ping the SNP were not uniquely aligned, SNPs with quality
scores less than 50, SNPs overlapping with repeat regions
[22], SNPs within 5 bp of indels and SNPs located within
regions with exceptionally high read coverage [23]. We
considered only SNPs that passed both the model filter
and the hard filter for all subsequent analysis presented
here.
Table 1 shows a summary of the identified SNPs. Among
all CTCF ChIP samples, the total number of SNPs discov-
ered was proportional to the number of aligned reads, with
an average of about 150,000 SNPs per individual. Since
different transcription factors have different binding
properties, the same number of reads may lead to different
genome coverage. For example, RNAPII ChIP-seq in
GM12878 had more aligned reads than H3K4me3 ChIP-
seq, but the fraction of the genome covered by more than
5 reads in RNAPII ChIP-seq (0.55%) was less than that in
H3K4me3 ChIP-seq. As a result, more SNPs were discov-
ered in H3K4me3 ChIP-seq than in RNAPII. The transi-
tion to transversion ratio (Ti/Tv) for de novo identified
SNPs was around 2.1, close to what is estimated in
mammals [19,24].
SNPs discovered from ChIP-seq overlap well with 1000
genomes project SNPs
In the pilot phase of the 1000 Genomes Project, two
trios with both parents and a child (CEU and YRI) weresequenced to an average depth of 42X coverage, and
complete genotype information for these six individuals
was published [4]. To test whether the SNPs we discov-
ered from our ChIP-seq data from these samples were in
agreement with the published genotypes, we performed
overlap analysis between SNPs discovered from CTCF
ChIP-seq and those published by the 1000 Genomes
Project (Pilot 2 SNPs, July, 2010 release).
More than 90% of the SNPs we identified de novo
using CTCF ChIP-seq data in the previously resequenced
cell lines overlapped Pilot 2 SNP calls. Because DNA
recovered after ChIP represents only a small portion of
the genome, we discovered only 3-7% of all Pilot 2 SNPs.
However, if we considered only Pilot 2 SNPs within
regions where we had at least 5X coverage in the CTCF
ChIP, more than 70% of such Pilot 2 SNPs were recov-
ered in our discovery (Table 2). Furthermore, the percent
recovery of Pilot 2 SNPs in ChIP-ed regions correlated
well with the proportion of the genome covered in ChIP-
ed regions (Additional file 1: Figure S2). SNPs we discov-
ered from ChIPseq datasets for RNAPII and H3K4me3
in GM12878 also showed the same high overlap with
Pilot 2 SNPs in this cell line (Table 2).
To independently verify SNPs found in ChIP-seq data,
we carried out Sanger sequencing of genomic DNA at
several randomly selected loci. We examined a total of
133 sites across 8 cell lines. All tested sites except for six
were confirmed to be correctly identified SNPs, suggest-
ing a 5% error rate for our ChIP-seq genotypes (Table 2,
Additional file 1: Figure S3). However, 2 of these 6
discrepancies were cases where the genotype called by
ChIP-seq matched the 1000 Genomes genotype, and in
the remaining cases, either the alleles identified by ChIP-
seq matched the alleles known to occur at that location,
or the discrepancy could be explained by low sequencing
coverage by ChIP-seq, suggesting that our error rate is in
fact lower (Additional file 1: Table S1).
The overlap between ChIP and Pilot 2 SNPs described
above consider a SNP as overlapping between the two sets
when their location and the called alt allele was the same.
If we required an exact genotype match between the two
sets, the percent overlap was somewhat lower (Additional
file 1: Figure S4A). ChIP SNPs had a lower heterozygosity
rate than Pilot 2 SNPs, suggesting that some heterozygous
SNPs had insufficient read coverage and therefore were
called homozygous (Additional file 1: Figure S4B). If we fil-
tered out SNPs with low read coverage, the heterozygosity
rate of ChIP SNPs was similar to that of Pilot 2 SNPs, and
the exact genotype overlap between ChIP SNPs and Pilot
2 SNPs was also restored to about 90% (Additional file 1:
Figure S4C). We were also able to identify small indels
from ChIP-seq data and the majority of these indels also
overlapped with those called by the 1000 Genomes Project
(Additional file 1: Table S2).
Table 2 Quality assessment of the discovered SNPs. Pilot 2 SNPs are identified by the 1000 Genomes Project
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GM12878 CTCF 112,999 94.14% 3.85% 11,908 75.37% 15/17 4/5
GM12891 CTCF 137,056 90.39% 4.55% 12,837 74.12% 13/13 4/4
GM12892 CTCF 206,349 92.23% 6.95% 20,772 76.54% 13/13 7/7
GM19238 CTCF 154,211 92.25% 4.47% 18,863 74.50% 11/11 3/3
GM19239 CTCF 153,092 94.33% 4.43% 14,844 70.37% 15/15 2/2
GM19240 CTCF 144,088 94.48% 4.08% 17,143 74.09% 10/10 3/3
GM12878 RNAPII 152,071 93.45% 5.14% 8,368 77.84% 5/6 2/2
GM12878 H3K4me3 200,675 93.19% 6.76% 44,755 79.40% 1/1 1/1
FB8470 CTCF 173,336 N/A N/A N/A N/A N/A 0/0
H1 ESC CTCF 94,398 N/A N/A N/A N/A N/A 0/0
Progeria CTCF 220,871 N/A N/A N/A N/A N/A 7/7
HUVEC CTCF 55,492 N/A N/A N/A N/A N/A 7/7
Progeria RNAPII 150,157 N/A N/A N/A N/A N/A 5/7
G1000 SNPs are ChIP-seq discovered SNPs that overlap with Pilot 2 SNPs. N/A is not applicable, as these cells were not genotyped by the 1000 Genomes Project.
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SNPs are qualitatively similar
In order to characterize in more detail the SNPs we
discovered de novo from ChIP-seq data, we separated
them into SNPs that overlapped with those found by the
1000 Genomes Project Pilot 2 dataset (referred to here
as G1000 SNPs) and those that were not found in Pilot 2
and were therefore novel (novel SNPs). First, we estab-
lished by genomic sequencing that our novel SNPs were
as accurate as G1000 SNPs (Table 2, Additional file 1:
Figure S3). We next investigated whether G1000 SNPs
were different from novel SNPs in terms of their quality
metrics. SNP quality scores reported by the GATK pipe-
line are Phred-scaled probability scores of the existence
of a polymorphism. We found that the median quality
scores of novel SNPs were equal to or greater than the
mean quality scores of G1000 SNPs (Figure 1A). We
then compared the genotype scores which represent the
confidence of the genotype called between G1000 SNPs
and novel SNPs, and found that novel SNPs had equal or
higher genotype scores than G1000 SNPs (Figure 1B).
We also examined the distribution of SNPs among six
individuals. If novel SNPs were largely erroneous, they
might be expected to be found in a single individual but
not shared across multiple individuals. However, more
than half of the novel SNPs we found were observed in
at least 3 individuals and the overall distribution across
individuals was also indistinguishable between G1000
and novel SNPs (Figure 1C, Additional file 1: Figure S5).
Finally, we checked our novel SNPs against the larger set
of SNP calls made by the 1000 Genomes project at low
coverage across a large number of individuals from thesame populations. 71% - 86% of the SNPs that were
novel in a given cell type were indeed found in other
individuals in the low coverage set, suggesting that they
were not spurious (Additional file 1: Table S3).
Genomic and chromosomal distribution of discovered
SNPs
We examined the genomic distribution of the SNPs we
identified from ChIP-seq data. Compared with Pilot 2
SNPs, a larger proportion of the SNPs we discovered
from RNAPII and H3K4me3 ChIP-seq data were loca-
lized to the 5’ UTR, reflecting RNAPII and H3K4me3
localization over the transcription start site (TSS) region
(Figure 2A). In contrast, SNPs from CTCF ChIP-seq data
showed a genomic location profile similar to Pilot 2
SNPs, both in the GM12878 lymphoblastoid cell line and
in a Progeria fibroblast line (Figure 2A), reflecting the
distinct binding distribution of CTCF.
When SNP discovery is carried out using ChIP-seq
data, it might be expected that the highest SNP density
occurs around significant ChIP peaks which are
identified on the basis of normalized read coverage.
We therefore investigated the distance between identi-
fied SNPs and the corresponding ChIP peak positions.
Most SNPs from CTCF ChIP-seq data were indeed
localized around −200 to +200 bp from CTCF peak
binding positions, but interestingly, the number of
CTCF SNPs dropped at the very center of CTCF peaks
(Figure 2B). Since CTCF is evolutionarily conserved
and its binding sites are also believed to be well con-
served [25], we tested whether CTCF binding peaks



















































































Figure 1 G1000 SNPs and novel SNPs are qualitatively similar. (A) SNP quality scores and (B) genotype quality scores of the G1000 SNPs and
novel SNPs are shown for each of the indicated cell lines as standard box-plots. G1000 SNPs are those identified de novo from ChIP-seq data but
overlap with the 1000 Genomes Project Pilot 2 SNP calls. (C) Individual distribution of SNPs. G1000 SNPs and novel SNPs discovered in GM12878
and GM19240 CTCF samples were categorized according to their individual distribution. For example, ‘1’ represents SNPs found in only one of the
six individuals, ‘2’ represents SNPs found in two individuals, etc.
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vertebrate species [26] were profiled around CTCF
peaks, a sharp increase in conservation was observed
at CTCF binding centers (Figure 2 C). The lower
density of de novo SNPs that we observed at the
centers of CTCF binding peaks is therefore likely due
to increased evolutionary constraint at CTCF binding
sites. We also observed a similar drop in SNP density
of 1000 Genomes Project SNPs in at the center of
CTCF binding sites (Additional file 1: Figure S6A).
In contrast to CTCF SNPs, SNPs discovered from
RNAPII ChIP-seq data showed only a modest enrich-
ment around RNAPII binding peaks (Figure 2D).Phylogenetic conversation was higher over a broader
range around RNAPII peak centers (Figure 2E) where
the Pilot 2 SNP density was also lower (Additional
file 1: Figure S6B). This lower overall SNP density
around RNAPII binding sites as well as at TSS
(Additional file 1: Figure S6C) may minimize any
potential increase in the discovery of SNPs at
RNAPII binding sites from RNAPII ChIP-seq data.
Analysis of the chromosomal distribution of SNPs
discovered from CTCF ChIP-seq data showed that the
relative SNP density on the X chromosome was
markedly lower than that of the autosomes























































































Distance to GM12878 RNAPII peak
to
intergenic
Figure 2 Properties of discovered SNPs. (A) SNP distribution relative to annotated genes. CTCF, H3K4me3 and RNAPII refer to SNPs discovered
from ChIP-seq data. (B) Distribution of GM12878 CTCF SNPs around ChIP peaks. 10 bp bins were generated from the highest points of peaks and
the number of SNPs was counted in each bin. SNP counts were added up across all peaks in every bin and plotted. (C) Distribution of
conservation scores around GM12878 CTCF peaks. Conservation scores were assigned to each of the 10 bp bins and the average was plotted.
(D) Distribution of GM12878 RNAPII SNPs and (E) phastCons conservation scores around GM12878 RNAPII ChIP peaks.
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because when we analyzed Pilot 2 SNPs, we saw that
the X chromosome similarly had a lower SNP density
than autosomes (Figure 3B). The more pronounced
bias for the X chromosome within SNPs discovered
from ChIP-seq data (compare Figures 3A and 3B) is
not a SNP calling artifact because when we calculated
the density of Pilot 2 SNPs within CTCF binding
sites, the relative X chromosome SNP density was
likewise lower than that of autosomes (Figure 3 C).SNP discovery from ChIP-seq data is proportional to
sequencing depth
From SNP discovery with CTCF ChIP-seq data in mul-
tiple cell lines, we found that the number of SNPs dis-
covered varied considerably between cell lines (Table 1).
Because the sequencing depth, that is, the total amount
of sequence generated, differed between cell lines, we
asked whether the difference in sequencing depths con-
tributes to the difference in number of SNPs discovered.





















































Figure 3 Chromosomal distribution of SNPs. Chromosomal
distribution of SNPs is plotted as SNPs/Mb. Chromosome number is
shown on the X axis. Data is shown for (A) GM12878 CTCF SNPs
(B) GM12878 Pilot 2 SNPs and (C) Pilot 2 SNPs within GM12878 CTCF
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Figure 4 Read depth and SNP discovery. (A) Correlation between
total number of discovery SNPs and number of aligned reads. The
number of discovered SNPs from CTCF ChIP-seq in 10 cell lines was
plotted against the number of aligned reads in each cell line. (B)
Effect of increasing read depth on SNP discovery. A random sample
as indicated on the X axis was taken from Progeria CTCF ChIP-seq
reads and SNP discovery was performed using this subset of reads.
The number of SNPs discovered in each sample as well as number
of SNPs discovered in ChIP-ed regions (with at least 5X read
coverage) is plotted. ChIP-ed regions were defined with the full set
of reads (100% of the total reads).
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(Figure 4A).
Since SNPs within transcription factor binding regions
are of the greatest interest from the perspective of
understanding how genetic variation affects transcription
factor binding, we were interested in understanding howincreased sequencing depth affected SNP discovery in
those ChIP-ed regions. For this purpose, we used CTCF
ChIP-seq data in Progeria fibroblasts where we had the
greatest sequencing depth. We defined ChIP-ed regions
as regions covered by 5 or more reads and analyzed the
total number of SNPs, and SNPs discovered within
ChIP-ed regions as a function of sequencing depth.
While the total number of discovered SNPs increased
linearly with increasing sequencing depth, the number of
SNPs within ChIP-ed regions increased more slowly and
almost plateaued after ~32 million reads. Furthermore,
with increased sequencing depth, the percent of total
SNPs within ChIP-ed regions decreased, suggesting that
the additional SNPs discovered with deeper sequencing
occur outside of the ChIP-ed regions and are therefore
less likely to be relevant for transcription factor binding
(Figure 4B).
Consistent allele-specific binding bias at SNPs discovered
from ChIP-seq data
We have previously found that at a subset of assayable
transcription factor binding sites, CTCF displays an al-
lelic binding bias in that there is significant difference in
its occupancy of the two alleles [16]. This allele-specific
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to be heritable. Our ability to accurately identify SNPs de
novo from ChIP-seq data in principle enables us to de-
tect allele-specific transcription factor binding bias even
in the absence of prior genotype information. To confirm
this, we first performed allele-specific binding bias ana-
lysis at SNP sites discovered de novo from CTCF ChIP-
seq data in the six lymphoblastoid cell lines (Methods).
A pairwise comparison of binding bias between two
individuals, at shared heterozygous SNPs where the bias
was statistically significant in at least one of the two indi-
viduals, showed that binding biases were largely
concordant across individuals (Figure 5). The Spearman
correlation coefficients of the binding biases between
individuals were positive and highly significant in every
case (Figure 5 inset tables). In particular, the bias values
for most SNPs were located in the upper right or lower
left quadrants, indicating that the direction of the







































Figure 5 Bias analysis with discovery SNPs. Each plot is a scatter plot of
shared heterozygous SNPs between two individuals as indicated on the top
two individuals with an FDR corrected P-value less than 0.05 are included. T
two individuals (top) and the Spearman P-values (bottom).results with SNPs we discovered de novo from ChIP-seq
data recapitulate the findings from previous analysis
which used then available genotypes released by the
1000 Genomes Project, and were mirrored in a similar
analysis we performed using a more recent set of
genotyped SNPs from the 1000 Genomes Project Pilot 2
release (Additional file 1: Figure S7). The set of signifi-
cantly biased de novo discovered SNPs included in
Figure 5 and the set of significantly biased Pilot 2 SNPs
also overlap well (Additional file 1: Table S4).
We then extended this bias analysis to normal and
disease fibroblasts that had not been previously
genotyped, and found CTCF allelic binding bias between
these two lines was similarly well correlated (Additional
file 1: Figure S8). Thus, de novo SNP discovery using
ChIP-seq data allows the measurement of allele-specific
binding in the absence of any genotyping information
and confirms the genetic basis of such allele-specific



























GM12878 GM12891 GM12892 GM19238 GM19239
0.488 GM12891
0.564 0.471 GM12892
0.684 0.591 0.452 GM19238
0.526 0.457 0.624 0.786 GM19239
0.611 0.476 0.487 0.708 0.642 GM19240
nce bias
percent reference allele (reads with reference allele/total reads) at
and right. SNPs that were significantly biased in at least one of the
he inset tables show the Spearman correlation of the bias between
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coding disease-associated variants
To assess the biological utility of SNPs discovered directly
from ChIP-seq data, we examined their overlap with SNPs
that have been associated with human diseases through
GWA studies [1]. Only 8 out of every 10,000 SNPs that
were identified in the 1000 Genomes Pilot 2 Project were
associated with a disease, but this proportion more than
doubled when we looked at the ChIP-seq SNPs we identi-
fied. 17 out of every 10,000 SNPs that we found de novo by
ChIP-seq overlapped with a disease associated SNP
(Figure 6A). By restricting this overlap analysis to those de
novo ChIP-seq SNPs that were also found in Pilot 2, we
determined that this enrichment for disease SNPs within
the ChIP-seq dataset is highly significant (P=8.2 x 10-99 by
hypergeometric probability distribution). We found that a
similarly higher proportion of ChIP-seq SNPs that we
discovered across other cell lines that had not been
genotyped by the 1000 Genomes project overlapped with
disease-associated SNPs (Figure 6A).-500 -300 -100 0 100 300
Distance to GWAS locus in bp
0 5 10 15
Number of GWAS SNPs per 10,000 SNP
Enrichment of GWAS SNPs











 +/- 500 bp 2
 +/- 2500 bp 6
 +/- 5000 bp 1
A
B
Figure 6 SNPs discovered from ChIP-seq and disease-associated SNPs
by the 1000 Genomes Project Pilot 2 set (1000 Genomes trio) or discovered
with diseases based on the NHGRI GWAS catalog (www.genome.gov/gwas
novo from ChIP-seq data that were also called by the 1000 Genomes Pilot
ChIP-seq data generated by us in cell lines that were not genotyped by the
ChIP-seq data from other ENCODE labs in cell lines that were not genotype
SNPs. Each point represents a significantly biased allele-specific binding eve
are all allele-specific binding loci within +/− 500 bp of a GWAS site (which
allele-specific binding in different individuals. (C) An example from the set
indicated by red dots in 'B' correspond to the heterozygous sites in 'C'. The
individuals. When heterozygous, the pie chart indicates relative occupancyAllele-specific binding biases could potentially reveal
differences between normal and disease risk alleles, espe-
cially at non-coding SNPs. We therefore analyzed if any
of the significantly biased allele-specific binding sites that
we identified after genotyping and allele-specific analysis
occurred near disease-associated SNPs identified by
GWAS. We identified dozens of cases of significant
allele-specific binding at distances ranging from 500 bp
to 5 kb from SNPs associated with various diseases
(Figure 6B, Additional file 1: Table S5). Since this size
range is well below the median haplotype block size of
about 45 kb in humans [3,27,28], a majority of these
allele-specific binding sites we have identified are likely
to occur on the same haplotype block as the GWAS
SNP. An example of such a SNP is shown in Figure 6C.
In cells (GM19238 and GM19240) where the loci are
heterozygous, the A allele is preferentially bound by
CTCF. Consistent with this, in cells that have two
G alleles at this location (GM19239, FB8460 and
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from ChIP-seq data in this study (ChIP-seq), that were also associated
tudies) are shown. ChIP-seq Set 1 refers to those SNPs discovered de
2, to allow direct comparison. ChIP-seq Set 2 refers to SNPs called from
1000 Genomes Project. ChIP-seq Set 3 refers to SNPs called from
d by the 1000 Genomes Project. (B) Allele-specific binding near GWAS
nt of CTCF at the indicated distance from a GWAS locus. Shown here
would be at position 0). Multiple points at the same distance represent
of allele-specific binding sites near a GWAS SNP. The two sites
read density of ChIP-seq data at the binding site is shown in selected
of the two alleles.
Ni et al. BMC Genetics 2012, 13:46 Page 10 of 13
http://www.biomedcentral.com/1471-2156/13/46heterozygous sites. When they occur on the appropriate
haplotypes, such allele-specific binding in non-coding
regions could effectively represent a functional distinc-
tion between the nearby normal and risk alleles.
Discussion
SNP discovery and transcription factor binding allelic bias
analysis from ChIPseq data
We developed an approach to simultaneously discover
SNPs and perform transcription factor binding bias analysis
using ChIP-seq data. Over 90% of our discovered SNPs in
six human lymphoblastoid cell lines overlap with the SNPs
identified by the 1000 Genomes Project (Table 1). A similar
proportion of SNPs that we discovered but were missed by
the 1000 Genomes Project were in fact accurate as checked
by Sanger sequencing. From the point of view of using such
discovered SNPs to assess allele-specific binding events, the
small number of cases where a heterozygous site is
misidentified as homozygous do not constitute a problem
since they are effectively "false negative" sites which would
not be assayable for allele-specificity. Most discovered SNPs
were close to transcription factor binding sites and the
distribution of SNPs mimicked that of ChIP peaks (Figure 2).
Due to the selectivity of ChIP, only a small fraction of all
known SNPs were discovered; however, the majority of
SNPs within ChIP-ed regions and therefore at transcription
factor binding sites were recovered (Table 1). Furthermore,
although increasing read depth leads to more SNPs, most
SNPs in ChIP-ed regions were discovered with 20–30
million reads, which is a typical ChIP-seq dataset, suggest-
ing that this type of analysis does not require very deep
sequencing (Figure 4B).
The difference in SNP density on the X chromosome
relative to autosomes is interesting. Many factors can
lead to a difference in diversity between the X chromo-
some and autosomes, such as different effective popula-
tion size, male mutation bias and natural selection
[29,30]. We speculate that variants in functional regions
on the X chromosome, for example, at transcription fac-
tor binding sites, are subject to a stronger natural selec-
tion bias than similar mutations on autosomes owing to
the hemizygosity of the X chromosome. The difference
in SNP density between the X chromosome and auto-
somes is therefore larger in SNPs discovered from CTCF
ChIP-seq data, which are focused on functional regions,
than in 1000 Genomes Project SNPs, which are largely
intergenic.
Utility of SNP genotyping from ChIP-seq and related data
Since many disease-associated polymorphisms are in non-
coding regions and are believed to affect gene regulation, a
subset of such variants could affect transcription factor
binding, chromatin structure or RNA processing. Determin-
ing the allelic effects of disease-associated SNPs ontranscription factor binding, histone modifications, DNA
methylation or DNaseI hypersensitivity would therefore be
a powerful approach to directly assess the functional regula-
tory impact of non-coding polymorphisms. While it is of
greatest interest to perform such studies on patient samples,
one limitation is that complete genotypes are rarely avail-
able for primary patient samples. Our approach overcomes
this limitation by enabling genotyping (SNP calling) and as-
sessment of allele-specific effects directly from the ChIP or
other functional experimental data, without requiring a sep-
arate genotyping dataset. We found that SNPs at transcrip-
tion factor binding sites discovered from ChIP-seq data
show an overrepresentation of disease-associated SNPs.
Interestingly, previous studies have also shown an enrich-
ment of GWAS SNPs in active intergenic chromatin
regions that are defined partly by high CTCF binding [31].
Additionally, we found that many allele-specific binding
events occur near non-coding disease-associated variants
identified by GWAS. Such allele-specific binding potentially
represents a functional distinction between the normal and
disease alleles, which is currently not known for the major-
ity of non-coding disease variants identified by GWAS. We
readily identified the examples shown in Figure 6 and
Additional file 1: Table S5 by analysis of a small number of
ChIP-seq datasets. Similar analysis as we describe here,
applied to the systematic datasets of genome-wide
transcription factor binding, chromatin status, and gene
expression will undoubtedly identify such distinctions for
many more disease-associated loci, which can then be
tested in patient samples.
While genotyping using arrays or deep sequencing
might appear to be straightforward, arrays generally
cover only a small subset of all possible polymorphisms,
and whole genome resequencing requires far deeper se-
quencing coverage than required for typical ChIP-seq or
RNA-seq assays. The fact that we could identify and ver-
ify SNPs that were missed in the 1000 Genomes Project
genotypes suggests that the selective focus of our
method on biochemically functional elements offers an
advantage even over whole-genome sequencing, likely
because our sequencing coverage over these loci is
higher at these enriched loci. While it is possible that a
subset of phenotypic effects are due to rare "private" var-
iants, distinguishing whether a rare non-coding variant
has a functional consequence or is neutral is challenging.
The approach outlined here can not only identify such
rare variants but also immediately establish whether it
significantly affects the experimental assay that was used
to identify it in the first place. We propose that by ana-
logy to exome sequencing which is aimed at identifying
variants in coding regions, the approach we have used
here can be considered to be "targetome" sequencing, in
which variants in functional non-coding regions are
identified along with information on how these variants
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potential, technical issues are likely to arise in certain
domains. For example, one application might be to
evaluate the allelic effects of non-coding somatic muta-
tions and germline polymorphisms in cancer, a disease
where the underlying affected cells are readily identifi-
able (as tumors) and can be isolated for experimental
analysis. However, cancer cells are often aneuploid and
tumor samples from patients are often genetically
heterogeneous, so bias analysis for transcription factor
binding or chromatin must account for the background
allele composition. SNP arrays have been used to deter-
mine copy number differences in cancer cells [32], so in
parallel to ChIP-seq analysis as outlined here, it should
be possible to determine the copy number of each allele
in the input genomic DNA from the same sample, and
use this quantitative information as the background
while calculating the significance of any allele-specific
binding bias.
Although our study focused on ChIP-seq data,
combining ChIP-seq and RNA-seq allele-specific analysis
in the same samples will clarify the relationship between
non-coding regulatory polymorphisms and allele-specific
gene expression. Since transcription factor and chroma-
tin changes are likely some distance away from the
transcribed region along the linear chromosome, such an
understanding will also require knowledge of SNP
phasing along individual chromosomes, but haplotype
inference based on statistical approaches or direct haplo-
type resolved sequencing methods can fill this gap
[33,34]. Allele-specific events of all types can thus be
measured in primary and disease cells and will shed light
on how genotypic variation corresponds to variation in
phenotype, including diseases.
Conclusions
Our approach demonstrates that it is possible to discover
SNPs with very high accuracy and simultaneously
perform transcription factor binding bias analysis directly
from ChIP-seq data. While the overwhelming majority of
SNPs discovered from ChIP-seq data coincide with
published genotype data, the small number of novel
SNPs that we found appear to be indistinguishable from
previously published variants based on several criteria.
Using SNPs discovered de novo from ChIP-seq data, we
confirmed and extended previous observations that
allele-specific biases tend to occur towards the same
allele across individuals and are therefore consistent with
an underlying genetic basis for these binding differences.
SNPs discovered from ChIP-seq data are strongly
enriched for disease-associated variants, and allele-
specific binding at many of these SNPs could allow a
functional distinction to be made between normal and
disease haplotypes.Methods
Data source
All CTCF and RNAPII ChIP-seq and peak finding was
performed by our group as described earlier [18] and
the data is available from the ENCODE project web
site (http://genome.ucsc.edu/ENCODE/). H3K4me3 and
H3K27me3 ChIP-seq data was also downloaded from the
ENCODE website. RNA-seq data for GM12891 was from
a previously published study [35]. The statistics of these
data sets are in Table 1 and Additional file 1: Table S6.
1000 Genome Project SNP calls were as in their Pilot 2
release [4]. The NHGRI GWAS catalog (www.genome.
gov/gwastudies) was downloaded and the data as accessed
on Feb 23 2012 was used for our analysis.
SNP calling with GATK
Raw ChIP-seq sequencing reads were aligned to the human
reference genome NCBI36 (hg18) with BWA [21]. To en-
sure optimal alignment, we used the reference genome pro-
vided with GATK that contained all 24 chromosome
sequences as well as additional contigs that have not been
assembled. GATK was then used to mark duplicated reads,
realign around insertions/deletions and recalibrate quality
scores for the alignments. The Unified Genotyper was used
to generate initial SNP calls in vcf format which was then
further filtered. The initial SNP calls were evaluated with a
Gaussian Mixture Model (GATK Variant Recalibrator) and
outliers were discarded. After this initial filtering, the SNPs
in the following categories were then filtered out: more than
2 SNPs within 10 base pairs, more than 10% overlapping
reads are not uniquely mapped, SNPs with quality scores
less than 50, SNPs overlapping with repeat regions [22],
SNPs within 5 bp of insertions/deletions, SNPs located
within regions with exceptionally high read coverage [23].
Allelic binding bias analysis
Bias analysis was performed as described previously [16].
To avoid alignment biases favoring reads containing the
reference allele, we constructed individual-specific reference
genomes that contained the SNPs discovered in that
individual from the ChIP-seq data, representing both the
reference and the alternate allele in the case of heterozygous
SNPs. We then carried out a second round of alignments to
these individual-specific genomes. We counted the number
of reads covering each allele at heterozygous SNPs and
expressed the ChIP-seq binding bias as the proportion of
reads that contain the reference allele. We calculated the
significance of this bias using a binomial model, assuming
under the null hypothesis that both alleles of a heterozygous
SNP would be equally represented in the ChIP DNA.
P-values were corrected for multiple testing using the false
discovery rate (FDR) on the set of SNPs where the differ-
ence of allele counts between the two alleles was at least 6.
The lists of significantly biased binding sites from de novo
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Pilot 2 SNPs are provided as Additional file 2: Table S7
and Additional file 3: Table S8 respectively.
Additional filesAdditional file 1: Figure S1. Diagram of SNP discovery pipeline. Figure
S2. Numbers of Pilot 2 SNPs rediscovered correlate with ChIP-seq coverage.
For each trio cell line, the percentage of Pilot 2 SNPs rediscovered with
ChIP-seq data is plotted together with percent of the genome with at least
5X coverage from ChIP-seq. Figure S3. Validation of de novo discovered
SNPs by genomic sequencing. The top row shows examples of SNPs
discovered de novo from ChIP-seq data that were also genotyped in that
individual by the 1000 Genomes Pilot 2 Project. The remainder are examples
of SNPs discovered de novo from ChIP-seq data but missed in the 1000
Genomes Pilot 2 set in that individual (GM cell lines) or found in
ungenotyped lines (HUVEC, Progeria). The top of each panel shows the
genomic DNA sequence, with the SNP at the center in bold. Chromosomal
coordinates, transcription factor/histone modification, and cell line are listed
below the chromatogram. Figure S4. SNP calling in low coverage regions.
(A) Location overlap and genotype overlap between CTCF ChIP-seq SNPs
and Pilot 2 SNPs. Location overlap is when the SNP location and alleles
match, but sometimes only one allele of a heterozygous genotype is
observed in the other set. Genotype overlap refers to an exact genotype
match. (B) Percent heterozygosity for CTCF ChIP-seq discovery SNPs and
Pilot 2 SNPs. (C) Read number filtering increases discovery SNP
heterozygosity and genotype overlap with Pilot 2 SNPs. SNPs covered by
less than the indicated number of reads were filtered out. Blue bars
represent the number of SNPs passing the filter. Red squares represent SNP
heterozygosity and green triangles represent the percent genotype overlap
with Pilot 2 SNPs, both on the secondary Y axis on the right. Figure S5.
Individual distribution of SNPs. G1000 SNPs and novel SNPs discovered in
the indicated GM cell lines. CTCF ChIP-seq samples were categorized
according to their individual distribution. ‘1’ represents SNPs found in only one
of the six individuals, ‘2’ represents SNPs found in two people and so on.
Figure S6. Pilot 2 SNP distribution around (A) CTCF and (B) RNAPII ChIP peak
centers and (C) transcription start sites. (D) Conservation scores around
transcription start sites. All distances are in bp. Figure S7. CTCF allelic binding
bias at Pilot 2 SNPs was plotted similarly as in Fig. 5. The inset tables show the
Spearman correlation coefficients (top) and Spearman P values (bottom).
Figure S8. CTCF allelic binding bias at discovered SNPs in Progeria and
FB8470 (normal) fibroblast cells. Table S1. Description of apparent errors. This
table lists all 6 discrepancies that we observed between genotypes called from
ChIP-seq data and our genomic Sanger sequencing validation (127 out of 133
were exactly correct). For errors 1 and 3, the ChIP-seq data recovered the
alternate allele and called it homozygous, but the reference allele was
apparently not observed at sufficient coverage. Errors 2 and 4 are discrepant
between the ChIP-seq and Sanger genotyping, but our ChIP-seq call matched
the 1000 Genomes Pilot 2 genotype. For errors 5 and 6, the ChIP-seq data
called it heterozygous and Sanger sequencing reported homozygous (similar
to errors 2and 4), but the two alleles reported by ChIP-seq correspond to the
two alleles known to occur at that position (in other individuals) according to
dbSNP 129. Table S2. Indels called from ChIP-seq data overlap with 1000
Genomes Project indel calls. Table S3. Novel SNPs found by ChIP-seq overlap
with SNPs found in other individuals in the same population in the 1000
Genomes Project low coverage data. Table S4. Overlap between biased (that
is, allele-specific) SNPs discovered from ChIP-seq data and biased Pilot 2 SNPs.
Table S5. Significantly biased allele-specific CTCF binding sites within 500 bp
of a GWAS SNP locus. P-val refers to the significance of the allele-specificity
binding bias at a heterozygous SNP. Table S6. SNP calling from H3K4me3
and/or H3K27me3 ChIP-seq data in 17 additional cell lines (ENCODE data) as
well as from RNA-seq data in GM12891 (from Toung et al., Genome Res. (2011)
21:991-8).
Additional file 2: CTCF allele-specific binding at SNPs discovered de novo
from CTCF ChIP-seq. SNPs with an FDR corrected bias P value of less than 0.05
are included. Each tab contains information for one individual.
Additional file 3: CTCF allele-specific binding at Pilot 2 SNPs. SNPs with an
FDR corrected bias P value of less than 0.05 are included. Each tab contains
information for one individual.Competing interests
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